Daiichi starts late-stage study of flu drug laninamivir

11/5/2009 | Reuters

Daiichi Sankyo commenced a Phase III trial of laninamivir, its inhaled drug candidate for H1N1 and bird flu infections. Daiichi plans to submit the drug for approval by March and launch it a year later.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN